Authors
Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators
Published in
Lancet (London, England). Oct 26, 2026. Epub Oct 26, 2026.
Abstract
Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with platinum-based chemotherapy in participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR tyrosine kinase inhibitors (TKIs).
In this multicentre, randomised, open-label, phase 3 trial (PANKU-Lung01) conducted at 73 sites in China, eligible participants had EGFR-mutated locally advanced or metastatic non-squamous NSCLC, disease progression after third-generation EGFR TKIs, and had received no previous chemotherapy for advanced disease. Participants were randomly assigned (1:1) to receive iza-bren (2·5 mg/kg intravenously on days 1 and 8 of each 3-week cycle) or pemetrexed plus carboplatin or cisplatin for four to six cycles, with pemetrexed maintenance permitted in participants without progression. The primary endpoint was progression-free survival assessed by blinded independent central review (BICR). The primary analysis included all randomly assigned participants who received at least one dose of study treatment (modified intention-to-treat population). We report the prespecified final progression-free survival and interim overall survival analyses. This trial is registered with ClinicalTrials.gov, NCT06382116.
Between May 22, 2024, and Sept 1, 2025, we screened 654 participants. After 222 (34%) were excluded, 432 (66%) participants were randomly assigned to iza-bren (n=217 [50%]) or chemotherapy (n=215 [50%]); 422 (98%) received study treatment (216 [51%] in the iza-bren group and 206 [49%] in the chemotherapy group) and comprised the modified intention-to-treat population. At the data cutoff (July 15, 2026; median follow-up for progression-free survival 14·6 months [95% CI 12·9-16·7] in the iza-bren group vs 15·2 months [11·2-18·2] in the chemotherapy group), median BICR-assessed progression-free survival was 11·1 months (9·2-12·7) with iza-bren versus 5·7 months (5·5-5·9) with chemotherapy (hazard ratio [HR] 0·40 [95% CI 0·31-0·51]; one-sided p<0·0001). Treatment-related adverse events of grade 3 or worse occurred in 170 (79%) of 216 participants in the iza-bren group and 128 (62%) of 206 in the chemotherapy group (predominantly haematological); treatment-related adverse events led to permanent discontinuation of at least one study-treatment component in four (2%) participants in each group and treatment-related deaths occurred in one participant in each group. Treatment-related interstitial lung disease occurred in two (1%) participants in the iza-bren group and none in the chemotherapy group.
In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related adverse events of grade 3 or worse were more frequent than with chemotherapy. To our knowledge, these findings provide the first phase 3 evidence for a bispecific antibody-drug conjugate and support iza-bren as a potential treatment option in this population.
Baili-Bio (Chengdu) Pharmaceutical.
PMID:
42933461
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 47
- Comments 0